Bharat Biotech filed patents for both vaccine candidates in July 2015 , Dr Ella informed . He said that since the company already worked on chikungunya , this was the next logical step . At the time we started working on the Zika vaccine , there was not a market incentive or any demand for it largely because the symptoms are mild . But we were already working in chukungunya and our hypothesis was that the same vector transmits this disease as well , so we thought we need to look at this aspect as well , he added .
